Your browser doesn't support javascript.
loading
Delays in Hepatitis A vaccination in people with HIV in Houston, Texas between 2010 and 2018.
Ciocca, Emily T; Staggers, Kristen A; Carey, Jennifer; Opekun, Antone R; Hollinger, F Blaine; Keitel, Wendy A; Atmar, Robert L; El Sahly, Hana M; Whitaker, Jennifer A.
Afiliação
  • Ciocca ET; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
  • Staggers KA; Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA.
  • Carey J; Harris Health System, Houston, TX, USA.
  • Opekun AR; Department of Medicine, Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX, USA.
  • Hollinger FB; Department of Medicine, Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX, USA.
  • Keitel WA; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
  • Atmar RL; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA.
  • El Sahly HM; Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, TX, USA.
  • Whitaker JA; Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, TX, USA.
Vaccine X ; 16: 100422, 2024 Jan.
Article em En | MEDLINE | ID: mdl-38192618
ABSTRACT

Background:

Studies have demonstrated low hepatitis A virus (HAV) vaccination rates among persons with HIV (PWH).

Methods:

We conducted a retrospective study of persons entering HIV care at two clinics in Houston, Texas between 2010 and 2018. We defined those eligible for HAV vaccination as those who had no history of HAV vaccination and had a negative anti-HAV IgG at entry to care. Kaplan-Meier curves summarized time to receipt of HAV vaccines. The proportions of patients who received 1 and 2 HAV vaccines at 6, 12, and 24 months were estimated. Cox proportional hazards regression evaluated associations between patient characteristics and vaccination. Significant factors were included in a multivariable Cox proportional hazards model.

Results:

Of 6,515 patients, 1372 were eligible for HAV vaccination. Of eligible patients, 29.2 % received 1 HAV vaccination at 6 months, 37.1 % at 12 months, and 47.8 % at 24 months. At 6 months, 10 % received 2 HAV vaccinations, 21.1 % at 12 months, and 33.4 % at 24 months. In multivariable analysis, men who have sex with men (adjusted HR 1.35, 95 % CI 1.06, 1.73) or those who had CD4 count ≥ 200 cells/µl (adjusted HR 2.52, 95 % CI 1.89, 3.37) had their second vaccination sooner than those who were not men who have sex with men or who had CD4 counts < 200 cells/µl, respectively. Patients > 50 years of age had their second vaccination sooner than those aged 30-50 years (adjusted HR 1.47, 95 % CI 1.08, 1.99). Those with active substance history had a longer time to second vaccination compared to those with no substance use history (adjusted HR 0.57, 95 % CI 0.40, 0.82).

Conclusions:

HAV vaccination rates were low and highlight the need for effective solutions to address HAV immunization gaps in PWH, especially among young patients, those with active substance use disorders, and those with significant immunocompromise.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Vaccine X Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Vaccine X Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos